The MISTRAL Study: Gut Microbiome Correlates of Serious AIDS and Non-AIDS Events

Condition(s) studied

Study summary

MISTRAL (Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications, antimicrobial drug resistance, and unresponsiveness to therapeutic HIV-1 vaccination) is a 5-year EU Horizon 2020 project, running from 1/1/2020 - 31/12/2025.

The project is led by Fundacio Privada Institut de Recerca de la Sida-Caixa CAIXA in Barcelona and aims to explore the gut microbiota in relation to HIV-1, seeking microbiome biomarkers to support development of interventions that mitigate infection and enhance response to vaccines and therapies.

If successful, MISTRAL will benefit millions of human beings living with, or at risk of acquiring HIV-1 infection, and will produce novel concepts and technical innovations applicable to other human diseases. By doing that, MISTRAL will help to unlock the full clinical potential of the human microbiome to stratify patient outcomes and will irreversibly bring microbiome science closer to clinical practice

Eligibility

Primary outcome measure(s)

• Incidence of serious AIDS and non-AIDS events — From date of enrolment until lost to follow-up or death, whichever came first, assessed up to 5 years
  In particular cardiovascular events, across Europe; and multi-omics (in particular gut microbiome), demographic, dietary, clinical, therapeutic, immunological and viral factors associated with these outcomes

Trial sites (22)

More Rigshospitalet, Denmark trials in Italy

Other trials for the same condition